Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Bristol-Myers Squibb ( (BMY) ).
At Bristol-Myers Squibb’s Annual Meeting held on May 5, 2026, shareholders elected all 11 board nominees to serve as directors until the 2027 Annual Meeting, reinforcing continuity in the company’s governance and strategic oversight. Investors also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026.
Shareholders backed the company’s 2026 stock award and incentive plan, signaling support for its approach to aligning executive and employee incentives with long-term performance and shareholder returns. However, a shareholder proposal to require the board chair to be an independent director failed, indicating investors were not prepared to mandate a split of leadership roles and suggesting continued confidence in the current board leadership structure.
The most recent analyst rating on (BMY) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Bristol-Myers Squibb stock, see the BMY Stock Forecast page.
Spark’s Take on BMY Stock
According to Spark, TipRanks’ AI Analyst, BMY is a Neutral.
The score is driven by solid current profitability and cash generation plus constructive guidance and growth-portfolio momentum. The main offsets are balance-sheet leverage (reduced flexibility) and identifiable near-term risks (margin pressure, legacy generic erosion, and pipeline binary readouts), while technicals and valuation are supportive but not decisive.
To see Spark’s full report on BMY stock, click here.
More about Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines, primarily in oncology, immunology, cardiovascular and fibrosis. The company targets serious diseases with high unmet medical need, competing in highly regulated, research-intensive markets where product pipelines, patent protection and capital allocation decisions are closely scrutinized by investors and healthcare stakeholders.
Average Trading Volume: 12,114,004
Technical Sentiment Signal: Strong Buy
Current Market Cap: $114.9B
Learn more about BMY stock on TipRanks’ Stock Analysis page.